Selective activity against proliferating tumor endothelial cells by CVX-22, a thrombospondin-1 mimetic CovX-Body

Area of Science:

• Oncology
• Immunology
• Vascular Biology

Background:

• Angiogenesis is crucial for tumor growth, involving the proliferation of tumor endothelial cells (TECs).
• Targeting tumor vasculature is a key anti-cancer strategy.
• CVX-22 is a novel therapeutic agent designed to target angiogenesis.

Purpose of the Study:

• To elucidate the anti-angiogenic mechanism of CVX-22.
• To investigate the effects of CVX-22 on TEC subsets in melanoma models.

Main Methods:

• Analysis of TEC numbers and proliferation in B16 and C32 melanoma models.
• Examination of vascular endothelial growth factor receptor 2 (VEGFR2)-positive TECs.
• In vitro and in vivo apoptosis assays.

Main Results:

• CVX-22 treatment significantly reduced the number of activated, VEGFR2-positive TECs.
• A substantial decrease (82%) in overall TEC proliferation (BrdU labeling) was observed.
• CVX-22 induced endothelial cell apoptosis, without altering proliferation rates or VEGFR2 density in the remaining VEGFR2-positive TECs.

Conclusions:

• CVX-22 selectively eliminates activated, VEGFR2-positive TECs through apoptosis.
• The specificity of CVX-22 for tumor vasculature may stem from the overrepresentation of activated TECs at angiogenic sites.